Generation Bio Co. Common Stock earnings per share and revenue
On Nov 05, 2025, GBIO reported earnings of -0.82 USD per share (EPS) for Q3 25, beating the estimate of -3.23 USD, resulting in a 74.68% surprise. Revenue reached 1.59 million, compared to an expected 673.20 thousand, with a 136.78% difference. The market reacted with a -3.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -5.00 USD, with revenue projected to reach 442.00 thousand USD, implying an increase of 509.76% EPS, and decrease of -72.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Generation Bio Co. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Generation Bio Co. Common Stock reported EPS of -$0.82, beating estimates by 74.68%, and revenue of $1.59M, 136.78% above expectations.
How did the market react to Generation Bio Co. Common Stock's Q3 2025 earnings?
The stock price moved down -3.28%, changed from $5.19 before the earnings release to $5.02 the day after.
When is Generation Bio Co. Common Stock expected to report next?
The next earning report is scheduled for Mar 11, 2026.
What are the forecasts for Generation Bio Co. Common Stock's next earnings report?
Based on 7
analysts, Generation Bio Co. Common Stock is expected to report EPS of -$5.00 and revenue of $442.00K for Q4 2025.